Companies/Medivolve Inc.

Company profile

Medivolve Inc.

OTC: MEDVF · Healthcare · Medical - Diagnostics & Research

Canadian filerHQ Toronto, ONReports USD

#924 of 1,394 Healthcare companies by revenuebottom-quartile growth

EA Score

——

FH —DQ —GM —SS 39

v0.1 · 5/100 weight · pillars only

↑ listing tenure, disclosure history · ↓ market scale, return on assets

Methodology →

Revenue TTM

$682.3k

Rev growth YoY (TTM)

-93.8%

Net income (FY)

-$12.2M

Employees

Market cap

$2.7k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$508.6k686.5k CAD2023

Net income-$12.2M-16.5M CAD2023

Operating income-$2.7M-3.6M CAD2023

Total assets$1.8M2.4M CAD2023

Liabilities$13.9M18.3M CAD2023

Equity-$11.9M-15.8M CAD2023

Revenue trend

FY2017 – FY2023 · USD

FY17

$13.6k

FY18

-$114.5k

FY19

$7.9M

FY20

$69.3M

FY21

$1.1M

FY22

$508.6k

FY23

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Medivolve Inc. booked $508.6k in FY2023 revenue, contracting 52% year over year — slower than 83% of Healthcare companies we track, at a -2397.5% net margin.

Peers · Healthcare

Neurobiological Technologies, Inc.——Syros Pharmaceuticals, Inc.——Corix Bioscience, Inc.——Hydrogen Hybrid Technologies, Inc.——

Key facts

CEONeil Said

SectorHealthcare

IndustryMedical - Diagnostics & Research

HeadquartersToronto, ON

ExchangeOTC: MEDVF

Employees25

IPO date2009-12-18

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.